期刊文献+

不同载体非诺贝特固体分散体的表征、溶出度和抑晶作用的对比研究 被引量:4

Comparisons of Characterization,Dissolution and Crystallization Inhibition Effect of Different Fenofibrate Solid Dispersions
原文传递
导出
摘要 分别以Soluplus?、聚乙二醇(PEG)6000和泊洛沙姆188为载体,采用熔融淬冷技术制备了药物-载体质量比为1∶3的非诺贝特固体分散体,并以扫描电镜(SEM)、粉末X-射线衍射(PXRD)和差示扫描量热(DSC)技术进行表征。PXRD和DSC数据表明,非诺贝特在3种固体分散体中均主要以无定形状态存在。以Soluplus?为载体时,水中固体分散体中非诺贝特的溶出率(60 min时)及溶解度(25℃)显著高于其他两种固体分散体及物理混合物(P〈0.05)。在非诺贝特超饱和的状态下,含有Soluplus?的水溶液中非诺贝特1 h时的溶解度为20.4μg/ml,显著高于含有另两种聚合物的水溶液(P〈0.05),表现出更好的结晶抑制效应。 Fenofibrate solid dispersions with Soluplus, polyethylene glycol (PEG) 6000 or poloxamer 188 as the carrier in 1 : 3 drug to carrier ratio were prepared by melt-quenching method and characterized by scanning electron microscopy (SEM), powder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC). The results of PXRD and DSC indicated that fenofibrate existed in an amorphous form in three kinds of solid dispersions. The dissolution at 60 min and solubility at 25℃ of fenofibrate from the solid dispersions with Soluplus as the carrier in water were significantly higher than those from the other two solid dispersions and physical mixtures (P〈0.05). When fenofibrate existed in a supersaturated state in the solution containing Soluplus, the solubility of fenofibrate at 1 h was 20.4 μg/ml, which was significantly higher than that in solutions containing the other two polymers (P〈0.05). It indicated that the crystallization inhibition effect of Soluplus was the best among three polymers.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2016年第8期1016-1021,共6页 Chinese Journal of Pharmaceuticals
基金 吉林省教育厅资助项目(吉教科合字2015第401号) 中国博士后科学基金面上项目(2015M571374) 吉林省科技发展计划资助项目(20160520046JH) 吉林省科技发展计划项目(20140311110YY) 吉林市科技发展计划项目(编号201464053)
关键词 非诺贝特 固体分散体 表征 溶出度 抑制结晶 fenofibrate solid dispersion characterization dissolution crystallization inhibition
  • 相关文献

参考文献12

  • 1Amidon GL, Lennernis H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability [J]. Pharm Res, 1995, 12 (3) : 413-420.
  • 2Lohani S, Cooper H, Jin X, et al. Physicochemical properties, form, and formulation selection strategy for a biopharmaceutical classification system class II preclinical drug candidate [J]. JPharm Sci, 2014, 103(10): 3007-302l.
  • 3Fong SY, Ibisogly A, Bauer-Brandl A. Solubility enhancement of BCS Class II drug by solid phospholipid dispersions: Spray drying versus freeze-drying [J]. Int J Pharm, 2015, 496 (2) : 382--391.
  • 4Bhamagar P, Dhote V, Mahajan SC, et al. Solid dispersion in pharmaceutical drug development: from basics to clinical applications [J]. CurrDrugDeliv, 2014, 11 (2) : 155--171.
  • 5Bikiaris DN. Solid dispersions, part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs [J]. Expert Opin DrugDeliv, 2011, 8(11): 1501--1519.
  • 6Shi NQ, Lei YS, Song LM, et al. Impact of amorphous and semicrystalline polymers on the dissolution and crystallization inhibition ofpioglitazone solid dispersions [J]. Powder Technol, 2013, 247:211--221.
  • 7Shi NQ, Yao J, Wang XL. Effect of polymers and media type on extending the dissolution of amorphous pioglitazone and inhibiting the recrystallization from a supersaturated state [J]. DrugDevlndPharm, 2014,40(8): 1112 1122.
  • 8Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? [J]. JPharm Sci, 2009, 98 (8) : 2549--2572.
  • 9Kawakami K. Modification ofphysicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs [J]. Adv Drug Deliv Rev, 2012, 64 (6) : 480-7495.
  • 10Xu S, Dai WG. Drug precipitation inhibitors in supersaturable formulations [J]. IntJPharm, 2013, 453 (1) : 3643.

同被引文献75

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部